File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A pooled analysis

TitleHuman papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A pooled analysis
Authors
Issue Date2015
Citation
Cancer Epidemiology Biomarkers and Prevention, 2015, v. 24, n. 4, p. 683-689 How to Cite?
Abstract© 2015 AACR. Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ⠥ 484 and < 1,000] or (ii) high seroreactivity (MFI ⠥1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. Results: Thirty-two (0.7%)HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8] , and seropositivity againstHPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observedwithmoderateHPV16 E6 seroreactivity. Conclusions: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. Impact: Some HPV16 E6 seropositive individuals without diagnosedHPV-drivencancer,especiallythosewithseropositivityagainst other HPV16 proteins, may harbor a biologically relevant HPV16 infection. Cancer Epidemiol Biomarkers Prev; 24(4); 683-9.
Persistent Identifierhttp://hdl.handle.net/10722/249104
ISSN
2023 Impact Factor: 3.7
2023 SCImago Journal Rankings: 1.688
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLang Kuhs, Krystle A.-
dc.contributor.authorAnantharaman, Devasena-
dc.contributor.authorWaterboer, Tim-
dc.contributor.authorJohansson, Mattias-
dc.contributor.authorBrennan, Paul-
dc.contributor.authorMichel, Angelika-
dc.contributor.authorWillhauck-Fleckenstein, Martina-
dc.contributor.authorPurdue, Mark P.-
dc.contributor.authorHolcátová, Ivana-
dc.contributor.authorAhrens, Wolfgang-
dc.contributor.authorLagiou, Pagona-
dc.contributor.authorPolesel, Jerry-
dc.contributor.authorSimonato, Lorenzo-
dc.contributor.authorMerletti, Franco-
dc.contributor.authorHealy, Claire M.-
dc.contributor.authorKjaerheim, Kristina-
dc.contributor.authorConway, David I.-
dc.contributor.authorMacfarlane, Tatiana V.-
dc.contributor.authorThomson, Peter-
dc.contributor.authorCastellsagué, Xavier-
dc.contributor.authorZnaor, Ariana-
dc.contributor.authorBlack, Amanda-
dc.contributor.authorHuang, Wen Yi-
dc.contributor.authorKrogh, Vittorio-
dc.contributor.authorTrichopoulou, Antonia-
dc.contributor.authorBueno-De-Mesquita, H. B.A.S.-
dc.contributor.authorClavel-Chapelon, Françoise-
dc.contributor.authorWeiderpass, Elisabete-
dc.contributor.authorEkström, Johanna-
dc.contributor.authorRiboli, Elio-
dc.contributor.authorTjønneland, Anne-
dc.contributor.authorSánchez, María José-
dc.contributor.authorTravis, Ruth C.-
dc.contributor.authorHildesheim, Allan-
dc.contributor.authorPawlita, Michael-
dc.contributor.authorKreimer, Aimée R.-
dc.date.accessioned2017-10-27T05:59:07Z-
dc.date.available2017-10-27T05:59:07Z-
dc.date.issued2015-
dc.identifier.citationCancer Epidemiology Biomarkers and Prevention, 2015, v. 24, n. 4, p. 683-689-
dc.identifier.issn1055-9965-
dc.identifier.urihttp://hdl.handle.net/10722/249104-
dc.description.abstract© 2015 AACR. Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ⠥ 484 and < 1,000] or (ii) high seroreactivity (MFI ⠥1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. Results: Thirty-two (0.7%)HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8] , and seropositivity againstHPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observedwithmoderateHPV16 E6 seroreactivity. Conclusions: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. Impact: Some HPV16 E6 seropositive individuals without diagnosedHPV-drivencancer,especiallythosewithseropositivityagainst other HPV16 proteins, may harbor a biologically relevant HPV16 infection. Cancer Epidemiol Biomarkers Prev; 24(4); 683-9.-
dc.languageeng-
dc.relation.ispartofCancer Epidemiology Biomarkers and Prevention-
dc.titleHuman papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A pooled analysis-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1158/1055-9965.EPI-14-1217-
dc.identifier.pmid25623733-
dc.identifier.scopuseid_2-s2.0-84925848405-
dc.identifier.volume24-
dc.identifier.issue4-
dc.identifier.spage683-
dc.identifier.epage689-
dc.identifier.isiWOS:000351955900006-
dc.identifier.issnl1055-9965-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats